Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 13/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | GAA | P10253 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | SNCA | P37840 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225916 | 0.92 | MAPT (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL29640485 | 0.92 | MAPT (0.59) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL225814 | 0.92 | NOX1 (0.47) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL239549 | 0.86 | NOX1 (0.65) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL225829 | 0.86 | NOX1 (0.65) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL2756739 | 0.85 | NOX1 (0.50) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL9980103 | 0.85 | NOX1 (0.54) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL10890272 | 0.81 | NOX1 (0.61) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL24255127 | 0.81 | MAPT (0.50) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL9391898 | 0.81 | SNCA (0.55) | NOX1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518111-B1 | COMPOSITION AND LUMINESCENT ELEMENT OBTAINED USING SAME | SUMITOMO CHEMICAL CO (JP) | 2019-03-13 | — | — | EP | disclosed |
| US-9780308-B2 | Composition and light emitting device using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9780308-B2 | Composition and light emitting device using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3002281-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2857394-A1 | Antiviral compounds | Gilead Pharmasset LLC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120306358-A1 | COMPOSITION AND LIGHT EMITTING DEVICE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120306358-A1 | COMPOSITION AND LIGHT EMITTING DEVICE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2518111-A1 | COMPOSITION AND LUMINESCENT ELEMENT OBTAINED USING SAME | Sumitomo Chemical Company, Limited (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NOX1 3704/4885MAPT 2923/4885GAA 151/4885 |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NOX1 3704/4885MAPT 2923/4885GAA 151/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NOX1 3704/4885MAPT 2923/4885GAA 151/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NOX1 3704/4885MAPT 2923/4885GAA 151/4885 |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NOX1 3704/4885MAPT 2923/4885GAA 151/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NOX1 3704/4885MAPT 2923/4885GAA 151/4885 |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NOX1 3704/4885MAPT 2923/4885GAA 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.